These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
107 related articles for article (PubMed ID: 28489483)
1. A low initial botulinum toxin A treatment response does not predict poor long-term outcomes in patients with axillary bromhidrosis. He J; Wang T; Dong J J Dermatolog Treat; 2018 Feb; 29(1):102-104. PubMed ID: 28489483 [TBL] [Abstract][Full Text] [Related]
2. Long-Term Safety and Efficacy of Botulinum Toxin A Treatment in Adolescent Patients with Axillary Bromhidrosis. Wang T; Dong J; He J Aesthetic Plast Surg; 2018 Apr; 42(2):560-564. PubMed ID: 29344685 [TBL] [Abstract][Full Text] [Related]
3. A close positive correlation between malodor and sweating as a marker for the treatment of axillary bromhidrosis with Botulinum toxin A. He J; Wang T; Dong J J Dermatolog Treat; 2012 Dec; 23(6):461-4. PubMed ID: 21801111 [TBL] [Abstract][Full Text] [Related]
4. Effectiveness of botulinum toxin A injection for the treatment of secondary axillary bromhidrosis. He J; Wang T; Dong J J Plast Reconstr Aesthet Surg; 2017 Nov; 70(11):1641-1645. PubMed ID: 28754234 [TBL] [Abstract][Full Text] [Related]
5. Efficacy and Safety of Botulinum Toxin A in Axillary Bromhidrosis and Associated Histological Changes in Sweat Glands: A Prospective Randomized Double-Blind Side-by-Side Comparison Clinical Study. Wu CJ; Chang CK; Wang CY; Liao YS; Chen SG Dermatol Surg; 2019 Dec; 45(12):1605-1609. PubMed ID: 30829777 [TBL] [Abstract][Full Text] [Related]
6. Treatment of focal hyperhidrosis with botulinum toxin type A: long-term follow-up in 61 patients. Schnider P; Moraru E; Kittler H; Binder M; Kranz G; Voller B; Auff E Br J Dermatol; 2001 Aug; 145(2):289-93. PubMed ID: 11531794 [TBL] [Abstract][Full Text] [Related]
7. Botulinum toxin type A in the treatment of bilateral primary axillary hyperhidrosis: efficacy and duration with repeated treatments. Lowe PL; Cerdan-Sanz S; Lowe NJ Dermatol Surg; 2003 May; 29(5):545-8. PubMed ID: 12752526 [TBL] [Abstract][Full Text] [Related]
8. Botulinum toxin type a is a safe and effective treatment for axillary hyperhidrosis over 16 months: a prospective study. Naumann M; Lowe NJ; Kumar CR; Hamm H; Arch Dermatol; 2003 Jun; 139(6):731-6. PubMed ID: 12810503 [TBL] [Abstract][Full Text] [Related]
9. Duration of efficacy increases with the repetition of botulinum toxin A injections in primary axillary hyperhidrosis: a study in 83 patients. Lecouflet M; Leux C; Fenot M; Célerier P; Maillard H J Am Acad Dermatol; 2013 Dec; 69(6):960-4. PubMed ID: 24035554 [TBL] [Abstract][Full Text] [Related]
10. Botulinum toxins types A and B for brow furrows: preliminary experiences with type B toxin dosing. Lowe NJ; Yamauchi PS; Lask GP; Patnaik R; Moore D J Cosmet Laser Ther; 2002 Mar; 4(1):15-8. PubMed ID: 12079632 [TBL] [Abstract][Full Text] [Related]
11. Long-term quantitative benefits of botulinum toxin type A in the treatment of axillary hyperhidrosis. Odderson IR Dermatol Surg; 2002 Jun; 28(6):480-3. PubMed ID: 12081675 [TBL] [Abstract][Full Text] [Related]
12. Botulinum toxin injections for chronic sialorrhoea in children are effective regardless of the degree of neurological dysfunction: A single tertiary institution experience. Mahadevan M; Gruber M; Bilish D; Edwards K; Davies-Payne D; van der Meer G Int J Pediatr Otorhinolaryngol; 2016 Sep; 88():142-5. PubMed ID: 27497402 [TBL] [Abstract][Full Text] [Related]
13. Local injection of botulinum toxin A: an alternative therapy for axillary osmidrosis. Xie A; Nie L; Tan Q J Dermatol; 2014 Feb; 41(2):153-6. PubMed ID: 24386960 [TBL] [Abstract][Full Text] [Related]
14. US-guided botulinum toxin injection for excessive drooling in children. Çiftçi T; Akıncı D; Yurttutan N; Akhan O Diagn Interv Radiol; 2013; 19(1):56-60. PubMed ID: 22798155 [TBL] [Abstract][Full Text] [Related]
15. Dilution of botulinum toxin A in lidocaine vs. in normal saline for the treatment of primary axillary hyperhidrosis: a double-blind, randomized, comparative preliminary study. Güleç AT J Eur Acad Dermatol Venereol; 2012 Mar; 26(3):314-8. PubMed ID: 21492253 [TBL] [Abstract][Full Text] [Related]
16. Treatment of facial chromhidrosis with botulinum toxin type A. Matarasso SL J Am Acad Dermatol; 2005 Jan; 52(1):89-91. PubMed ID: 15627085 [TBL] [Abstract][Full Text] [Related]
17. Treatment of focal idiopathic hyperhidrosis with Botulinum Toxin Type A: clinical predictive factors of relapse-free survival. Campanati A; Sandroni L; Gesuita R; Giuliano A; Giuliodori K; Marconi B; Ganzetti G; Offidani A J Eur Acad Dermatol Venereol; 2011 Aug; 25(8):917-21. PubMed ID: 21054569 [TBL] [Abstract][Full Text] [Related]
18. Initial North American experience with botulinum toxin type A for treatment of anismus. Joo JS; Agachan F; Wolff B; Nogueras JJ; Wexner SD Dis Colon Rectum; 1996 Oct; 39(10):1107-11. PubMed ID: 8831524 [TBL] [Abstract][Full Text] [Related]
19. Long-term botulinum toxin dose consistency for treatment of adductor spasmodic dysphonia. Holden PK; Vokes DE; Taylor MB; Till JA; Crumley RL Ann Otol Rhinol Laryngol; 2007 Dec; 116(12):891-6. PubMed ID: 18217507 [TBL] [Abstract][Full Text] [Related]
20. Long-term efficacy and safety of botulinum toxin A injections to treat blepharospasm and hemifacial spasm. Ababneh OH; Cetinkaya A; Kulwin DR Clin Exp Ophthalmol; 2014 Apr; 42(3):254-61. PubMed ID: 23844601 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]